Georgiamune

Georgiamune is a clinical-stage biotechnology company focused on transforming immunotherapy by reprogramming immune signaling pathways to restore immune homeostasis. Founded by Dr. Samir N. Khleif, the company has built a first-in-class target discovery platform that has generated a robust pipeline of immunomodulators — including dual-functioning antibodies and small molecule Treg inhibitors and activators — targeting cancer and autoimmune diseases. Georgiamune has advanced multiple assets into Phase 1 clinical trials, including GIM-531, GIM-407, and GIM-122, and continues to expand its pipeline with novel biologics and small molecules addressing large indications with high unmet need.